Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A CRISPR/Cas9 rodent model team-up
12-10-2018
by DDNews Staff  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

BURLINGTON, Mass.—MilliporeSigma, a leader in genome editing, disclosed today a strategic alliance in the CRISPR/Cas9 rodent model market with France-based biotechnology company genOway.
 
“We are committed to making our patented CRISPR technology broadly available to the global research and discovery community. Together with genOway, we will get the best research models out to the pharmaceutical and biotech industries as well as academic laboratories quickly, so we can help accelerate their research, shorten drug development timelines and treat previously untreatable diseases in faster and more targeted ways,” said Udit Batra, CEO, MilliporeSigma. “We will continue to play an active role, responsibly and ethically, in ensuring that scientists have access to the latest CRISPR technologies.”
 
Through an exclusive worldwide license of MilliporeSigma’s foundational CRISPR integration patents, genOway will develop new models and solutions allowing non-profit and for-profit scientists to use CRISPR/Cas9 technology. Under the agreement, genOway will also develop a network of sublicensees in both the model creation and distribution businesses and preclinical services for all potential applications worldwide, with a strong focus in the United States, Asia and Europe. Financial details were not disclosed.
 
Both MilliporeSigma and genOway have identified research fields where they can combine their respective technologies and expertise to develop and validate new CRISPR/Cas9-related products and solutions. MilliporeSigma’s patented CRISPR integration technology is a strong entry point through which the company believes innovation can be developed and launched.  
 
“The CRISPR/Cas9 IP landscape has been complex and uncertain over the last years,” noted Alexandre Fraichard, CEO of genOway. “The situation has changed and the MilliporeSigma IP portfolio is clearly central to CRISPR/Cas9-based eukaryotic genome-editing applications. This alliance, combining research and business, will enable us to provide the scientific community with more physiologically relevant models and the necessary intellectual property rights which will ultimately speed delivering better drugs to patients.”
 
At MilliporeSigma, excellence and expertise in animal care, use and welfare are a high priority. In line with its mission to develop innovative medicines and chemicals based on scientific excellence and the established ethical standards, MilliporeSigma is committed to conducting animal research activities only if no other method or testing is available for obtaining the result or product sought, not entailing the use of a live animal.
 
CRISPR technology is a core competency for MilliporeSigma, which has 14 years of experience with genome editing, spanning from discovery to manufacturing. MilliporeSigma recognizes that genome editing has resulted in major advancements in biological research and medicine.  At the same time, the growing potential of genome-editing technologies has opened scientific, legal and societal concerns. MilliporeSigma says they support research with genome editing under careful consideration of ethical and legal standards.
 
Code: E12101801

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.